Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

Abstract Background Preoperative chemoradiotherapy (CRT), the current standard of care for locally advanced rectal cancer (LARC), is associated with many radiotherapy (RT)-related side effects. We aimed to evaluate whether S-1 and oxaliplatin (SOX) or folinic acid, 5-FU, and oxaliplatin (mFOLFOX6) c...

Full description

Bibliographic Details
Main Authors: Keisuke Miwa, Eiji Oki, Masanobu Enomoto, Keisuke Ihara, Koji Ando, Fumihiko Fujita, Masahiro Tominaga, Shinichiro Mori, Goro Nakayama, Mototsugu Shimokawa, Hiroshi Saeki, Hideo Baba, Masaki Mori, Yoshito Akagi
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Rectal cancer
Neoadjuvant chemotherapy
Chemoradiotherapy
SOX
mFOLFOX6
Online Access:https://doi.org/10.1186/s12885-020-07766-5

Internet

https://doi.org/10.1186/s12885-020-07766-5

Similar Items